Researchers from Western Sydney University in Australia have developed a cutting-edge artificial intelligence (AI) tool that could revolutionize the diagnosis and treatment of Type 1 diabetes (T1D). This innovation enables more accurate risk prediction and helps tailor treatment responses, offering a promising shift in managing the autoimmune condition.
The new tool, powered by AI and informed by molecular data, introduces what the researchers call a Dynamic Risk Score for Classification (DRS4C). This score is based on microRNAs—small molecules found in blood that reflect dynamic biological changes—allowing clinicians to better assess whether an individual has or is at risk of developing T1D.
“Predicting Type 1 diabetes early is increasingly important, especially with emerging therapies that can delay its onset,” said Professor Anand Hardikar, the lead investigator from the university’s School of Medicine and Translational Health Research Institute. “Children diagnosed before age 10 face a significantly higher disease burden, including a shorter life expectancy, making early detection a critical step toward effective intervention.”
The findings, published in the journal Nature Medicine, are based on an analysis of nearly 6,000 samples from participants across seven countries, including India, Australia, the US, Canada, Denmark, Hong Kong, and New Zealand. The researchers validated their risk model in an independent set of 662 individuals, successfully identifying those who were likely to remain insulin-independent just one hour after treatment.
Beyond identifying T1D risk, the model shows promise in distinguishing between Type 1 and Type 2 diabetes, a critical diagnostic challenge in some cases.
Dr. Mugdha Joglekar, co-lead author from the same institute, emphasized how this approach differs from traditional genetic testing. “While genetic markers show long-term inherited risk—like living in a flood-prone area—dynamic risk scores reflect real-time risk, much like monitoring rising water levels. This allows clinicians to adapt treatment earlier, based on current biological conditions rather than fixed genetic predispositions.”
The AI-enabled tool offers a significant step forward in personalized medicine, empowering healthcare professionals with data-driven insights for timely intervention and better outcomes in diabetes care.
